Research ArticleOpen AccessGoogle Scholar indexed
Analysis of a Questionnaire Survey regarding Current Conditions against Exposure to Anticancer Drugs and Reports of Cancer Chemotherapy at Outpatient Departments in Japan
Department of Oncology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan
Department of Internal Medicine, Fukuoka Wajiro Hospital, Fukuoka, Japan
Department of Pharmacy, Hamanomachi Hospital, Fukuoka, Japan
Department of Pharmacy, Hamanomachi Hospital, Fukuoka, Japan
Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan
Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan
Department of Pharmacy, Fukuoka University Hospital, Fukuoka, Japan
Department of Practical Pharmaceutical Science, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan
Division of Medical Oncology, Hematology, and Infection Diseases, Fukuoka University Hospital, Fukuoka, Japan
Division of Medical Oncology, Hematology, and Infection Diseases, Fukuoka University Hospital, Fukuoka, Japan
Department of Pharmacy, Kurume University Hospital, Fukuoka, Japan
Division of Gastroenterology, Kurume University Department of Medicine, Fukuoka, Japan
Department of Pharmacy, National Kyushu Cancer Center, Fukuoka, Japan
Department of Gastrointestinal and Medical Oncology, National Kyushu Cancer Center, Fukuoka, Japan
Department of Pharmacy, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
Department of Pharmacy, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
Department of Pharmacy, Saga-Ken Medical Centre Koseikan, Saga, Japan
Department of Medical Oncology, Saga-Ken Medical Centre Koseikan, Saga, Japan
Department of Pharmacy, Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan
Department of Medicine and Comprehensive Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Department of Medical Oncology, Hamanomachi Hospital, Fukuoka, Japan
Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
- 1 Department of Oncology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan
- 2 Department of Internal Medicine, Fukuoka Wajiro Hospital, Fukuoka, Japan
- 3 Department of Pharmacy, Hamanomachi Hospital, Fukuoka, Japan
- 4 Department of Pharmacy, Hamanomachi Hospital, Fukuoka, Japan
- 5 Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan
- 6 Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan
- 7 Department of Pharmacy, Fukuoka University Hospital, Fukuoka, Japan
- 8 Department of Practical Pharmaceutical Science, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan
- 9 Division of Medical Oncology, Hematology, and Infection Diseases, Fukuoka University Hospital, Fukuoka, Japan
- 10 Division of Medical Oncology, Hematology, and Infection Diseases, Fukuoka University Hospital, Fukuoka, Japan
- 11 Department of Pharmacy, Kurume University Hospital, Fukuoka, Japan
- 12 Division of Gastroenterology, Kurume University Department of Medicine, Fukuoka, Japan
- 13 Department of Pharmacy, National Kyushu Cancer Center, Fukuoka, Japan
- 14 Department of Gastrointestinal and Medical Oncology, National Kyushu Cancer Center, Fukuoka, Japan
- 15 Department of Pharmacy, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
- 16 Department of Pharmacy, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
- 17 Department of Pharmacy, Saga-Ken Medical Centre Koseikan, Saga, Japan
- 18 Department of Medical Oncology, Saga-Ken Medical Centre Koseikan, Saga, Japan
- 19 Department of Pharmacy, Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan
- 20 Department of Medicine and Comprehensive Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
- 21 Department of Medical Oncology, Hamanomachi Hospital, Fukuoka, Japan
Pharmacology & Pharmacy·Volume 08 (2017)·Pages 140–152·Published 15 May 2017·DOI10.4236/pp.2017.85010
Copy link · social · email
Abstract
[Background] Medical staff have many occasions to be exposed to anticancer drugs (ACDs) in the process of performing cancer chemotherapy. Although guidelines for the safe handling of ACDs have been published, actual measures against exposure to ACDs differ between hospitals, and no surveillance data regarding the conditions of each hospital in relation to performing chemotherapy in Japan are available. [Methods] To understand current measures against exposure to ACDs and problems related to cancer chemotherapy at outpatient departments, we conducted a questionnaire survey on doctors, pharmacists, and nurses in 10 leading hospitals for cancer chemotherapy in Japan. [Results] Responses were received from all 10 institutions. The hospital pharmacists prepared all ACDs for outpatients in each institution. All hospitals took basic measures against ACD exposure, such as using personal protective equipment and penetration-resistant waste containers. Conditions against exposure to ACDs generally improved between 2012 and 2015, especially in terms of conveyance of ACDs and use of a closed-system drug transfer device. However, no measures linking ACDs with administration routes or injection sites were commonly taken in any of the hospitals in 2015. [Conclusions] Conditions against ACD exposure improved between 2012 and 2015, possibly because new guidelines were issued. To improve measures for ACD exposure in Japan, preparing more appropriate manuals and offering more opportunities to medical staff for continuing education are considered important.
KeywordsExposureAnticancer DrugsMeasurementPersonal Protective EquipmentOutpatient Service
- Stewart, B.W. and Wild, C.P. (2014) World Cancer Report 2014. World Health Organization Press, Geneva.
- Health and Social Statistics Division (2015) Vital Statistics, Statistics and Information Department Minister’s Secretariat Ministry of Health, Labour and Welfare, Japan.
- ASHP (American Society of Health-System Pharmacists) (1990) ASHP Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs. American Journal of Health-System Pharmacy, 47, 1033-1049.
- NIOSH (National Institution of Occupational Safety and Health) (2004) NIOSH Alert. Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. NIOSH, Atlanta.
- ONS (Oncology Nursing Society) (2011) Safe Handling of Hazardous Drugs. 2nd Edition, ONS, Pittsburgh.
- Krepinsky, A., Bryant, D.W., Davison, L., et al. (1990) Comparison of Three Assays for Genetic Effects of Antineoplastic Drugs on Cancer Patients and Their Nurses. Environmental and Molecular Mutagenesis, 15, 83-92. https://doi.org/10.1002/em.2850150205
- Valanis, B.G., Vollmer, W.M., Labuhn, K.T. and Glass, A.G. (1993) Acute Symptoms Associated with Antineoplastic Drug Handling among Nurses. Cancer Nursing, 16, 288-295. https://doi.org/10.1097/00002820-199308000-00005
- Kopjar, N. and Garaj-Vrhovac, V. (2001) Application of the Alkaline Comet Assay in Human Biomonitoring for Genotoxicity: A Study on Croatian Medical Personnel Handling Antineoplastic Drugs. Mutagenesis, 16, 71-78. https://doi.org/10.1093/mutage/16.1.71
- Jakab, M.G., Major, J. and Tompa, A. (2001) Follow-Up Genotoxicological Monitoring of Nurses Handling Antineoplastic Drugs. Journal of Toxicology and Environmental Health, 62, 307-318. https://doi.org/10.1080/152873901300018011
- OSHA (Occupational Safety and Health Administration) (1986) OSHA Work-Practice Guidelines for Personnel Dealing with Cytotoxic (Antineoplastic) Drugs. OSHA, Washington DC.
- ISOPP (International Society of Oncology Pharmacy Practitioners) (2007) Standards of Practice: Safe Handling of Cytotoxics. ISOPP, North Vancouver.
- Japanese Society of Hospital Pharmacists (2014) Manual of Preparations for Anti-Cancer Drugs. 3rd Edition, Japanese Society of Hospital Pharmacists, Jiho.
- ASHP (American Society of Health-System Pharmacists) (2006) ASHP Guidelines on Hazardous Drugs. ASHP, Bethesda.